While targeting a single cytokine like IL-1 might fall short of achieving clinically significant improvements due to the involvement of multiple inflammatory pathways in the prediabetic state, colchicine's impact on various pro-inflammatory cell types, cytokines, and pathways active in obesity and diabetes positions it as a comprehensive intervention [158, 197]. The gene discussed is IL1A; the disease is obesity due to melanocortin 4 receptor deficiency.